August 11, 2021 07:44 AM EDTUpdated 10:11 AM
Deals

As Ab­b­Vie and Soli­ton shake hands on a $550M merg­er, the FTC says 'not so fast'

Nicole DeFeudis

Editor

Back in May, Ab­b­Vie’s Al­ler­gan Aes­thet­ics unit signed away $550 mil­lion in cash to scoop up drug­mak­er Soli­ton and its body sculpt­ing de­vice Reson­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times